CSCR
MCID: CNT060
MIFTS: 38

Central Serous Chorioretinopathy (CSCR)

Categories: Bone diseases, Eye diseases, Immune diseases, Rare diseases

Aliases & Classifications for Central Serous Chorioretinopathy

MalaCards integrated aliases for Central Serous Chorioretinopathy:

Name: Central Serous Chorioretinopathy 52 58 71
Central Serous Chorioretinopathy After Bone Marrow Transplantation 52
Central Serous Choroidopathy 52
Cscr 58

Characteristics:

Orphanet epidemiological data:

58
central serous chorioretinopathy
Inheritance: Not applicable;

Classifications:

Orphanet: 58  
Rare eye diseases


External Ids:

ICD10 via Orphanet 33 H35.7
UMLS via Orphanet 72 C0730328
Orphanet 58 ORPHA443079
UMLS 71 C0730328

Summaries for Central Serous Chorioretinopathy

NIH Rare Diseases : 52 Central serous chorioretinopathy is a disease that causes fluid to build up under the retina , the back part of the inner eye that sends sight information to the brain. The fluid leaks from the choroid (the blood vessel layer under the retina). The cause of this condition is unknown but stress can be a risk factor . Signs and symptoms include dim and blurred blind spot in the center of vision, distortion of straight lines and seeing objects as smaller or farther away. Many cases of central serous chorioretinopathy improve without treatment after 1-2 months. Laser treatment may be an option for other individuals.

MalaCards based summary : Central Serous Chorioretinopathy, also known as central serous chorioretinopathy after bone marrow transplantation, is related to choroiditis and kuhnt-junius degeneration. An important gene associated with Central Serous Chorioretinopathy is CFH (Complement Factor H), and among its related pathways/superpathways are Complement and coagulation cascades and Cell adhesion_ECM remodeling. The drugs Bevacizumab and Verteporfin have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and bone marrow.

Related Diseases for Central Serous Chorioretinopathy

Diseases related to Central Serous Chorioretinopathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 251)
# Related Disease Score Top Affiliating Genes
1 choroiditis 31.2 CFH ARMS2
2 kuhnt-junius degeneration 30.8 CFH ARMS2
3 multifocal choroiditis 30.7 CFH ARMS2
4 macular degeneration, age-related, 1 30.7 CFH C4B ARMS2
5 angioid streaks 30.4 CFH ARMS2
6 antiphospholipid syndrome 30.0 SERPINE1 PLAT CFH
7 chronic kidney disease 29.3 SERPINE1 NR3C2 CFH
8 bestrophinopathy, autosomal recessive 11.8
9 retinal detachment 11.2
10 microvascular complications of diabetes 5 10.8
11 scotoma 10.7
12 macular retinal edema 10.7
13 sleep apnea 10.6
14 periodontal ehlers-danlos syndrome 10.6
15 uveitis 10.6
16 retinal disease 10.6
17 helicobacter pylori infection 10.5
18 vogt-koyanagi-harada disease 10.5
19 refractive error 10.5
20 eye disease 10.5
21 retinal vascular disease 10.5
22 retinal degeneration 10.5
23 yemenite deaf-blind hypopigmentation syndrome 10.4
24 joint laxity, short stature, and myopia 10.4
25 neuroretinitis 10.4
26 myopia 10.4
27 conn's syndrome 10.4
28 neuritis 10.4
29 retinitis 10.4
30 coronary heart disease 1 10.4
31 impotence 10.4
32 ulcerative colitis 10.4
33 optic nerve disease 10.3
34 hemangioma 10.3
35 sleep disorder 10.3
36 peptic ulcer disease 10.3
37 cataract 10.3
38 lupus erythematosus 10.3
39 47,xyy 10.3
40 multiple sclerosis 10.3
41 melanoma, cutaneous malignant 10 10.3
42 colitis 10.3
43 optic neuritis 10.3
44 posterior uveitis 10.3
45 telangiectasis 10.3
46 color blindness 10.3
47 acute retrobulbar neuritis 10.3
48 retinal vein occlusion 10.3
49 melanoma 10.3
50 adenoma 10.3

Graphical network of the top 20 diseases related to Central Serous Chorioretinopathy:



Diseases related to Central Serous Chorioretinopathy

Symptoms & Phenotypes for Central Serous Chorioretinopathy

Drugs & Therapeutics for Central Serous Chorioretinopathy

Drugs for Central Serous Chorioretinopathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 4 216974-75-3
2
Verteporfin Approved, Investigational Phase 4 129497-78-5
3
Ranibizumab Approved Phase 4 347396-82-1 459903
4
Eplerenone Approved Phase 4 107724-20-9 150310 443872
5
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
6
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
7 Mitogens Phase 4
8 Endothelial Growth Factors Phase 4
9 Antineoplastic Agents, Immunological Phase 4
10 Angiogenesis Inhibitors Phase 4
11 Dermatologic Agents Phase 4
12 Photosensitizing Agents Phase 4
13 Hormone Antagonists Phase 4
14 Hormones Phase 4
15 Mineralocorticoids Phase 4
16 Antihypertensive Agents Phase 4
17 Mineralocorticoid Receptor Antagonists Phase 4
18 diuretics Phase 4
19 Diuretics, Potassium Sparing Phase 4
20 Anti-Inflammatory Agents Phase 4
21 glucocorticoids Phase 4
22 Triamcinolone diacetate Phase 4
23 triamcinolone acetonide Phase 4
24 Triamcinolone hexacetonide Phase 4
25 Pharmaceutical Solutions Phase 4
26
Brinzolamide Approved Phase 2 138890-62-7 68844
27
leucovorin Approved Phase 2 58-05-9 6006 143
28
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
29
Selenium Approved, Investigational, Vet_approved Phase 2 7782-49-2
30
Zinc Approved, Investigational Phase 2 7440-66-6 32051
31
Tocopherol Approved, Investigational Phase 2 1406-66-2, 54-28-4 14986
32
Copper Approved, Investigational Phase 2 7440-50-8 27099
33
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
34
Amoxicillin Approved, Vet_approved Phase 1, Phase 2 26787-78-0 33613
35
Metronidazole Approved Phase 1, Phase 2 443-48-1 4173
36
Ketoconazole Approved, Investigational Phase 2 65277-42-1 47576
37
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
38
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
39
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
40
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
41
Mifepristone Approved, Investigational Phase 2 84371-65-3 55245
42
Spironolactone Approved Phase 1, Phase 2 52-01-7, 1952-01-7 5833
43
Sodium citrate Approved, Investigational Phase 2 68-04-2
44
Finasteride Approved Phase 2 98319-26-7 57363
45
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
46
Vitamin E Approved, Nutraceutical, Vet_approved Phase 2 59-02-9 14985
47
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 22737-96-8, 68-26-8, 11103-57-4 9904001 445354
48
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 2 83-88-5 493570
49
Lutein Approved, Investigational, Nutraceutical Phase 2 127-40-2 6433159
50
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 73)
# Name Status NCT ID Phase Drugs
1 Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population Completed NCT02462499 Phase 4 Inspra (eplerenone)
2 A Randomized, Double-masked, Multicenter, Controlled Study of Photodynamic Therapy in Patients With Central Serous Chorioretinopathy Completed NCT01574430 Phase 4
3 A Prospective Randomized Controlled Multicentre Trial Comparing Half-dose Photodynamic Therapy (PDT) With High-density Subthreshold Micropulse Laser Treatment in Patients With Chronic Central Serous Chorioretinopathy (CSC) Completed NCT01797861 Phase 4
4 The Role of Unilateral Intravitreal Bevacizumab (Avastin), for the Treatment of Bilateral Diabetic Macular Edema: a Pilot Study. Completed NCT00496405 Phase 4 bevacizumab
5 Cohort Study of the Clinical Course of Macular Diseases in Kagawa (Kagawa Macula Cohort Study) Recruiting NCT02321267 Phase 4 ranibizumab, aflibercept, pegaptanib, verteporphin
6 Study on Half-dose Photodynamic Therapy Versus Eplerenone in Chronic CenTRAl Serous Chorioretinopathy (SPECTRA Trial) Active, not recruiting NCT03079141 Phase 4 Eplerenone
7 Clinical Outcomes Following Randomization of Steroid Concentration in Patients With Glenohumeral Osteoarthritis Active, not recruiting NCT03586687 Phase 4 Triamcinolone
8 PRedictive Factors and Changes From Treatment in Idiopathic Polypoidal Choroidal Vasuclopathy Versus Central Serous Chorioretinopathy Versus Neovascular Age Related Macular Degeneration With afLibercept Not yet recruiting NCT02681783 Phase 4 aflibercept
9 Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Unknown status NCT00418431 Phase 2, Phase 3 Intravitreal injection of Bevacizumab
10 A Randomized, Double-masked, Placebo Controlled Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Unknown status NCT02215330 Phase 2, Phase 3 Eplerenone;Maltodextrin
11 A Prospective Non-inferiority Study of the Use of Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy Completed NCT02735213 Phase 2, Phase 3
12 Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT02153125 Phase 2 Eplerenone
13 Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy Unknown status NCT03542006 Phase 2 Brinzolamide Ophthalmic
14 Phase 2 Study of Escalating Oral Methotrexate for Central Serous Chorioretinopathy Unknown status NCT01633983 Phase 2 Methotrexate;Delayed treatment
15 Intravitreal Aflibercept Injection for Persistent Central Serous Chorioretinopathy: A Prospective Pilot Study Completed NCT01710332 Phase 2 Intravitreal Aflibercept Injection
16 Eplerenone for Central Serous Chorioretinopathy: A Pilot Study Completed NCT01822561 Phase 2 Eplerenone 50mg
17 High-dose Antioxidants for Central Serous Chorioretinopathy Completed NCT00963131 Phase 2 antioxidants tablets
18 Effect of Helicobacter Pylori Treatment on Remission of Idiopathic Central Serous Chorioretinopathy (ICSCR) Completed NCT00817245 Phase 1, Phase 2 omeprazole, Amoxicillin, metronidazole
19 Pilot Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT00837252 Phase 1, Phase 2 Finasteride
20 A Pilot Study of The Treatment of Central Serous Chorioretinopathy With Ketoconazole. Completed NCT00211393 Phase 2 ketoconazole
21 Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate Completed NCT00489840 Phase 1, Phase 2 Anecortave Acetate Sterile suspension 15 mg;Anecortave Acetate
22 Prospective Study on the Efficacy and Safety of Intravitreal Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01325181 Phase 1, Phase 2 Verteporfin;ranibizumab
23 Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC) Completed NCT02354170 Phase 2 Mifepristone;Placebo
24 Extension Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Completed NCT01227993 Phase 1, Phase 2 Finasteride
25 Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Chorioretinopathy: A Prospective Randomized Controlled Trial Completed NCT00987077 Phase 2
26 Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Completed NCT01971190 Phase 2 Intravitreal Aflibercept injection;Sham injection
27 Pilot Phase I/II Study of the Treatment of Classic Central Serous Chorioretinopathy With Topical Interferon Gamma-1b Completed NCT01468337 Phase 1, Phase 2 Interferon gamma-1b
28 Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Completed NCT00211445 Phase 2 verteporfin
29 Evaluation de la Spironolactone Dans le Traitement Des choriorétinites séreuses Centrales Non résolutives à Trois Mois Completed NCT01552044 Phase 1, Phase 2 Spironolactone;Placebo
30 Phase 2 Study of Non-damaging Retinal Laser Therapy Using PASCAL Laser With Endpoint Management Software for Macular Diseases Recruiting NCT01975103 Phase 2
31 Sildenafil for Treatment of Choroidal Ischemia Recruiting NCT04356716 Phase 2 Sildenafil
32 Phase II, Randomized, Placebo-Controlled Study for the Evaluation of Finasteride in the Treatment of Chronic Central Serous Chorioretinopathy Terminated NCT01585441 Phase 2 Finasteride;Placebo
33 Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid. Completed NCT00403325 Phase 1 rhuFab V2 [ranibizumab] ( Lucentis )
34 Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy Completed NCT02036632 Phase 1
35 Phase I Study of Sequestered Transscleral, Controlled-Release Celecoxib Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120636 Phase 1 Episcleral Celecoxib
36 Phase I Study of Sequestered Transscleral, Controlled-Release Dexamethasone Delivered Via Episcleral Reservoir for Treatment of Macular Edema & Inflammatory Disorders of the Eye Posterior Pole Including Sclera, Choroid, Retina or Vitreous Recruiting NCT04120311 Phase 1 Episcleral Dexamethasone
37 Intraocular Concentrations of Growth Factors and Cytokines in Chronic Central Serous Chorioretinopathy And the Effect of Therapy With Bevacizumab Unknown status NCT00864773
38 Analysis of Plasminogen Activator Inhibitor-1 Level in Chronic Serous Chorioretinopathy and Polypoidal Choroidal Vasculopathy Unknown status NCT02815176
39 The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Unknown status NCT01630863
40 Pseudo-PDT in Central Serous Chorioretinopathy Unknown status NCT02799992
41 Swept Source Enhanced Depth Imaging Optical Coherence Tomography (SS-EDI-OCT) and Study of the Retina, Choroid and Sclera in Health and Disease Unknown status NCT02443129
42 Selective RPE Laser Treatment (SRT) for Various Macular Diseases Unknown status NCT00403884
43 Eplerenone for the Treatment of Central Serous Chorioretinopathy Completed NCT01990677 25mg Eplerenone;Placebo
44 Choroidal Thickness Measurements During CSCR Treatment Applying EDI-OCT Technology Completed NCT01610804
45 Persona of Central Serous Chorioretinopathy Completed NCT02819622
46 Effects of Optical Coherence Tomography Angiography-guided Photodynamic Therapy in Acute Central Serous Chorioretinopathy Completed NCT03497000
47 Treatment of Chronic Recalcitrant or Unresponsive Central Serous Chorioretinopathy Via Electromagnetic Stimulation And Platelet- Rich Plasma Completed NCT04224831
48 Central Serous Chorioretinopathy: An Observational Study About Etiology, Course and Prognosis Completed NCT01378130
49 Comparison of Multifocal Electroretinogram Assessment Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Completed NCT00803517
50 Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy: Evaluation by Fundus Autofluorescence and Spectral Domain Optical Coherence Tomography Completed NCT01327170

Search NIH Clinical Center for Central Serous Chorioretinopathy

Genetic Tests for Central Serous Chorioretinopathy

Anatomical Context for Central Serous Chorioretinopathy

MalaCards organs/tissues related to Central Serous Chorioretinopathy:

40
Eye, Retina, Bone Marrow, Bone, Brain, Endothelial, Testes

Publications for Central Serous Chorioretinopathy

Articles related to Central Serous Chorioretinopathy:

(show top 50) (show all 1961)
# Title Authors PMID Year
1
DIFFERENCE BETWEEN PACHYCHOROID AND NONPACHYCHOROID POLYPOIDAL CHOROIDAL VASCULOPATHY AND THEIR RESPONSE TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. 61
31181038 2020
2
Identifying central serous chorioretinopathy biomarkers in coexisting diabetic retinopathy: a multimodal imaging study. 61
31563867 2020
3
FUNDUS AUTOFLUORESCENCE PATTERNS IN CENTRAL SEROUS CHORIORETINOPATHY. 61
31157711 2020
4
Systemic oxidative stress level in patients with central serous chorioretinopathy. 61
32266471 2020
5
USE OF CHOROIDAL VASCULARITY INDEX FOR CHOROIDAL STRUCTURAL EVALUATION IN CENTRAL SEROUS CHORIORETINOPATHY WITH CHOROIDAL NEOVASCULARIZATION. 61
31259812 2020
6
Fluorescein angiography as a primary guide for reduced-fluence photodynamic therapy for the treatment of chronic central serous chorioretinopathy. 61
32274613 2020
7
Predictors of treatment response to intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy for choroidal neovascularisation secondary to chronic central serous chorioretinopathy. 61
31615761 2020
8
Cerebral Neurovascular Coupling Impairment in Central Serous Chorioretinopathy. 61
32564029 2020
9
Prospective Impact of Sildenafil on Chronic cEntral Serous chorioretinopathy. 61
32525054 2020
10
Microrip of Retinal Pigment Epithelium in Central Serous Chorioretinopathy. 61
32525538 2020
11
Intraocular gnathostomiasis and central serous chorioretinopathy. 61
32506596 2020
12
Purtscher-like retinopathy in adult-onset Still's disease, complicated by treatment-related central serous chorioretinopathy. 61
32140617 2020
13
The Effect of Obstructive Sleep Apnea on Absolute Risk of Central Serous Chorioretinopathy. 61
32574769 2020
14
Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report. 61
32503484 2020
15
Photodynamic Therapy for Chorioretinal Diseases: A Practical Approach. 61
32279234 2020
16
Choroidal vascular densities of macular disease on ultra-widefield indocyanine green angiography. 61
32494872 2020
17
Hair cortisol concentrations in chronic central serous chorioretinopathy. 61
31608607 2020
18
Central serous chorioretinopathy: risk factors for serous retinal detachment in fellow eyes. 61
31473627 2020
19
Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy. 61
32532761 2020
20
Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy. 61
32170365 2020
21
COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY. 61
30897068 2020
22
Study of vessel density by optical coherence tomography angiography in patients with central serous chorioretinopathy after low-fluence photodynamic therapy. 61
32198017 2020
23
Quantitative analyses of diameter and running pattern of choroidal vessels in central serous chorioretinopathy by en face images. 61
32533066 2020
24
Relationship between photoreceptor layer changes before half-dose photodynamic therapy and functional and anatomic outcomes in central serous chorioretinopathy. 61
32546748 2020
25
Changes in choroidal blood flow velocity in patients diagnosed with central serous chorioretinopathy during follow-up for pachychoroid pigment epitheliopathy. 61
32215340 2020
26
Retinal structural changes in patients receiving tamoxifen therapy by spectral-domain optical coherence tomography. 61
32100607 2020
27
Novel insights into retinal neovascularization secondary to central serous chorioretinopathy using 3D optical coherence tomography angiography. 61
32123772 2020
28
Multimodal Imaging in the Management of Choroidal Neovascularization Secondary to Central Serous Chorioretinopathy. 61
32575806 2020
29
Central serous chorioretinopathy secondary to subtenon triamcinolone injection: A new hypothesis for the mechanism. 61
32496660 2020
30
[Indications for fluorescein angiography and optical coherence tomography angiography (OCTA) in medical retina: Changes from 2015 and 2018]. 61
32115267 2020
31
Outer retinal tubulations in central serous chorioretinopathy associated with choroidal neovascularisation. 61
32370611 2020
32
Hypoproteinemia as a parameter of poor perinatal/neonatal outcomes in women with preeclampsia diagnosed as hypertension plus proteinuria. 61
32492636 2020
33
Central serous chorioretinopathy and achromatopsia: a case report. 61
32424630 2020
34
Multicolour imaging in central serous chorioretinopathy. 61
31489701 2020
35
Oral medications for central serous chorioretinopathy: a literature review. 61
31527760 2020
36
PHOTORECEPTOR OUTER SEGMENT IS EXPANDED IN THE FELLOW EYE OF PATIENTS WITH UNILATERAL CENTRAL SEROUS CHORIORETINOPATHY. 61
32404847 2020
37
Commentary: Our understanding of central serous chorioretinopathy-coming a full circle? 61
32317462 2020
38
Commentary: Multicolor imaging: A new imaging tool in central serous chorioretinopathy. 61
32317465 2020
39
Response of neovascular central serous chorioretinopathy to an extended upload of anti-VEGF agents. 61
32112141 2020
40
Central serous chorioretinopathy: An update on risk factors, pathophysiology and imaging modalities. 61
32407978 2020
41
Monocyte to high-density lipoprotein and neutrophil-to-lymphocyte ratios in patients with acute central serous chorioretinopathy. 61
32317461 2020
42
Validation of multicolor imaging signatures of central serous chorioretinopathy lesions vis-a-vis conventional color fundus photographs. 61
32317464 2020
43
A comparative study of the choroidal vascularity indexes in the fellow eyes of patients with pachychoroid neovasculopathy and central serous chorioretinopathy by binarization method. 61
32415536 2020
44
CLINICAL APPLICATION OF MULTICOLOR IMAGING IN CENTRAL SEROUS CHORIORETINOPATHY. 61
30608348 2020
45
Efficacy of Adalimumab for Chronic Vogt-Koyanagi-Harada Disease Refractory to Conventional Corticosteroids and Immunosuppressive Therapy and Complicated by Central Serous Chorioretinopathy. 61
31268769 2020
46
THE INCIDENCE OF NEOVASCULARIZATION IN CENTRAL SEROUS CHORIORETINOPATHY BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 61
32310626 2020
47
A randomized clinical trial comparing prompt photodynamic therapy with 3 months observation in patients with acute central serous chorioretinopathy with central macular leakage. 61
32264706 2020
48
Pachychoroid disease: a new perspective on exudative maculopathy. 61
32318919 2020
49
Optical coherence tomography angiography in primary eye care. 61
32285493 2020
50
Scleral thinning surgery for bullous retinal detachment with retinal pigment epithelial tear in central serous chorioretinopathy: a case report. 61
32252699 2020

Variations for Central Serous Chorioretinopathy

Expression for Central Serous Chorioretinopathy

Search GEO for disease gene expression data for Central Serous Chorioretinopathy.

Pathways for Central Serous Chorioretinopathy

Pathways related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.09 SERPINE1 PLAT CFH C4B
2 10.94 SERPINE1 PLAT
3 10.07 SERPINE1 PLAT

GO Terms for Central Serous Chorioretinopathy

Cellular components related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.02 SLC7A5 SERPINE1 PLAT CFH C4B

Biological processes related to Central Serous Chorioretinopathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibrinolysis GO:0042730 8.62 SERPINE1 PLAT

Sources for Central Serous Chorioretinopathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....